Find Reports

Select Report Type

Reimbursement Review

Displaying 401 - 425 of 1422

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
teduglutide	Revestive	teduglutide	SR0606 Revestive - CDEC Final Recommendation November 21, 2019_For posting.pdf sr0606-revestive-clinical-review-report.pdf sr0606-revestive-pharmacoeconomic-review-report.pdf SR0606_Revestive_PI Submission.pdf	Short Bowel Syndrome (SBS), pediatrics	Reimburse with clinical criteria and/or conditions	Complete	May 29, 2019	Nov 19, 2019	SR0606-000
lanadelumab	Takhzyro	lanadelumab	SR0618 Takhzyro - CDEC Final Recommendation November 22, 2019_for posting.pdf sr0618-takhzyro-clinical-review-report.pdf sr0618-takhzyro-pharmacoeconomic-review-report.pdf SR0618 Takhzyro - Patient Input for Posting.pdf	Hereditary angioedema, prevention	Reimburse with clinical criteria and/or conditions	Complete	May 29, 2019	Nov 19, 2019	SR0618-000
cyclosporine	Verkazia	cyclosporine	SR0615 Verkazia - CDEC Final Recommendation December 6, 2019_For Posting.pdf sr0615-verkazia-clinical-review-report.pdf sr0615-verkazia-pharmacoeconomic-review-report.pdf SR0615_Verkazia_PI Submission1.pdf	Severe vernal keratoconjunctivitis, pediatric (≥4 years)	Reimburse with clinical criteria and/or conditions	Complete	May 22, 2019	Nov 18, 2019	SR0615-000
Larotrectinib for Neurotrophic...	Vitrakvi	Larotrectinib	LarotrectinibVitrakvi_NTRKLocallyAdvancedorMetastaticSolidTumours10159ProvFunding.pdf 10159LarotrectinibNTRK+SolidTumours_fnRec_REDACT_31Oct201_ChairApproved_final.pdf 10159LarotrectinibNTRK+SolidTumours_fnEGR_NOREDACT-ABBREV_Post_31Oct2019_final.pdf 10159LarotrectinibNTRK+SolidTumours_fnCGR_REDACT_Post_31Oct2019_final.pdf 10159LarotrectinibNTRK+SolidTumours_inRec_2019-08-27_ChairApproval_REDACT_Post_29Aug2019_final.pdf 10159LarotrectinibNTRK+SolidTumours_PAGFeedbackSummary_FINAL_Post_31Oct2019_final.pdf 10159LarotrectinibNTRK+SolidTumours_SponsorFeedback_2019-09-19_Post_31Oct2019_final.pdf 10159LarotrectinibNTRK+SolidTumours_PtFeedback_Combined_Post_31Oct2019_final.pdf 10159LarotrectinibNTRK+SolidTumours_Combined_ClinicianF-B_Post_31Oct2019_final.pdf 10159LarotrectinibNTRK+SolidTumours_Combined_COI_Post_31Oct2019_final_Redacted.pdf 10159LarotrectinibNTRK+SolidTumours_Clombined COI_Post_31Oct2019_final_Redacted.pdf	NTRKplus solid tumours	Do not reimburse	Complete	Feb 25, 2019	Oct 31, 2019	PC0159-000
Idhifa for Acute Myeloid Leuke...	Idhifa	Enasidenib	EnasidenibIdhifa_AML10144ProvFunding.pdf 10144EnasidenibAML_fnRec_ApprovedbyChair_Post_31Oct2019_final.pdf 10144EnasidenibAML_fnEGR_NOREDACT-ABBREV_Post_31Oct2019_final.pdf 10144EnasidenibAML_fnCGR_NOREDACT_Post_31Oct2019_final.pdf 10144EnasidenibAML_inRec_approvedbyChair_NOREDACT_Post_29Aug2019_final.pdf 10144EnasidenibAML_PAGFeedbackSummary_FINAL_Post_31Oct2019_final.pdf 10144EnasidenibAML_SponsorFeedback_2019-09-19_revised_Post_31Oct2019_final.pdf 10144EnasidenibAML_PatientFeedback_LLSC_2019-09-26_FINAL_Post_31Oct2019_final.pdf 10144EnasidenibAML_ClinicianFeedback_CCO_2019-09-11_Post_31Oct2019_final.pdf 10144EnasidenibAML_PatientInput_LLSC_COI_Post_31Oct2019_final.pdf 10144EnasidenibAML_Clinician_Combined_COI_Post_31Oct2019_final_Redacted.pdf	Acute myeloid leukemia (AML)	Do not reimburse	Complete	Apr 5, 2019	Oct 31, 2019	PC0144-000
insulin degludec + liraglutide	Xultophy	insulin degludec + liraglutide	SR0599 Xultophy - CDEC Final Recommendation October 28, 2019_redacted_For posting.pdf sr0599-xultophy-clinical-review-report.pdf sr0599-xultophy-pharmacoeconomic-review-report.pdf SR0599-Xultopy-Patient-Input.pdf	Diabetes mellitus, Type 2	Reimburse with clinical criteria and/or conditions	Complete	Jan 30, 2019	Oct 24, 2019	SR0599-000
onabotulinumtoxinA	Botox	onabotulinumtoxinA	SR0584 Botox Resubmission - CDEC Final Recommendation October 22, 2019_for posting.pdf sr0584-botox-clinical-review-report-resubmission.pdf sr0584-botox-pharmacoeconomic-review-report-resubmission.pdf SR0584 Botox Resubmission - Consolidated Patient Input_Dec 2018_Redacted.pdf	Migraine, chronic	Reimburse with clinical criteria and/or conditions	Complete	Nov 2, 2018	Oct 17, 2019	SR0584-000
Keytruda Metastatic Urothelial...	Keytruda	Pembrolizumab	PembrolizumabKeytruda_MUCfirstline10177ProvFunding.pdf 10177PembrolizumabMUC(firstline)_FnRec_REDACT_Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_fnEGR_NOREDACT-ABBREV_Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_fnCGR_REDACT_Post_03Oct2019_final.pdf 10177PembrolizumabMM(first line)_InRec_REDACT_Post_01Aug2019_final.pdf 10177PembrolizumabMUC(firstline)_PAGFeedbackSummary_FINAL_Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_SubmitterFeedback_2019-08-16_Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_PatientFeedback_BCC_2019-08-16__Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_ClinicianFeedback_CCO_2019-08-16_Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_PtGrp_COI_Post_03Oct2019_final_Redacted.pdf 10177PembrolizumabMUC(firstline)_Combined ClinicianCOIs_Post_03Oct2019_final.pdf	MUC First line	Do not reimburse	Complete	Feb 20, 2019	Oct 3, 2019	PC0177-000
dolutegravir / lamivudine	Dovato	dolutegravir / lamivudine	SR0601 Dovato - CDEC Final Recommendation October 2, 2019_for posting.pdf sr0601-dovato-clinical-review-report.pdf sr0601-dovato-pharmacoeconomic-review-report.pdf sr0601-dovato-patient-input.pdf	HIV-1 infection	Reimburse with clinical criteria and/or conditions	Complete	Feb 21, 2019	Sep 30, 2019	SR0601-000
fluocinolone acetonide intravi...	Iluvien	fluocinolone acetonide intravitreal implant	SR0608 Iluvien - CDEC Final Recommendation September 30, 2019_for posting.pdf sr0608-iIluvien-clinical-review-report.pdf sr0608-iIluvien-pharmacoeconomic-review-report.pdf SR0608-Iluvien-patient-input.pdf	diabetic macular edema	Do not reimburse	Complete	Apr 3, 2019	Sep 26, 2019	SR0608-000
Pomalyst in combination with d...	Pomalyst	Pomalidomide	PomalidomidePomalystDex&Bortez_MM2ndline10165_ProvFunding.pdf 10165PomalidomideBortezomibMM_fnRec_EarlyConv_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_fnEGR_NOREDACT-ABBREV_EarlyConv_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_fnCGR_REDACT_EarlyConv_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_InRec_approvedbyChair_Post_29Aug2019_final.pdf 10165PomalidomideBortezomibMM_PAGFeedbackSummary_FINAL_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_SubmitterFeedback_2019-09-13_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_ClinicianFeedback_CCO_2019-09-09_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_COI_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_Combined Clinician_COI_Post_18Sep2019_final.pdf	Multiple Myeloma	Reimburse with clinical criteria and/or conditions	Complete	Mar 15, 2019	Sep 18, 2019	PC0165-000
Trifluridine and Tipiracil (Lo...	Lonsurf	Trifluridine and Tipiracil	pcodr_provfund-10173-trifluridine-tipiracil_lonsurf_mcrc.pdf 10173Trifluridine-TipiracilmCRC_fnrec_Chair Approved_Post_29Aug2019_revised_final.pdf 10173Trifluridine-TipiracilmCRC_fnEGR_NOREDACT-ABBREV_Post_29Aug2019_final.pdf 10173Trifluridine-TipiracilmCRC_fnCGR_NOREDACT_Post_29Aug2019_final.pdf 10173Trifluridine-TipiracilmCRC_inRec_Chair approved_NOREDACT_Post_05Jul2019_final.pdf 10173Trifluridine-TipiracilmCRC_PAGFeedbackSummary_FINAL_2019-07-15_Post_29Aug2019_final.pdf 10173Trifluridine-TipiracilmCRC_SubmitterFeedback_2019-07-19_Post_29Aug2019_final.pdf 10173Trifluridine-TipiracilmCRC_PatientFeedback_CCC_2019-07-19_Post_29Aug2019_final.pdf 10173Trifluridine-TipiracilmCRC_ClinicianFeedback_Ko_2019-07-19_Post_29Aug2019_final.pdf 10173Trifluridine-TipiracilmCRC_Patient COIs_Post_29Aug2019_final_Redacted.pdf 10173Trifluridine-TipiracilmCRC_Clinicians COIs_Post_29Aug2019_final_Redacted.pdf	mCRC Resubmission	Do not reimburse	Complete	Jan 21, 2019	Aug 29, 2019	PC0173-000
Darzalex in combo with Bortezo...	Darzalex	Daratumumab	DaratumumabDarzalex_NewlyDiagnosedMM10148_ProvFunding.pdf 10148Daratumumab+VMPforMM_fnRec_REDACT_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_fnEGR_NOREDACT-ABBREV_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_fnCGR_REDACT_Post_29Aug2910_final.pdf 10148Daratumumab+VMPforMM_inRec_ApprovedbyChair_REDACT_Post_05Jul2019_final.pdf 10148Daratumumab+VMPforMM_PAGFeedbackSummary_FINAL_2019-07-16_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_SubmitterFeedback_2019-07-19_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_PatientFeedback_MC_2019-07-08_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_ClinicianFeedback_CCO_2019-07-15_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_PatientI_COI_Post_29Aug2019.pdf 10148Daratumumab+VMPforMM_Combined Clinician COIs_Post_28Aug2019_Redacted.pdf	BMP for Multiple Myeloma (newly diagnosed)	Reimburse with clinical criteria and/or conditions	Complete	Jan 4, 2019	Aug 29, 2019	PC0148-000
baricitinib	Olumiant	baricitinib	SR0597 Olumiant - Patient Group Input_February 7, 2019.pdf sr0597-olumiant-clinical-review-report.pdf sr0597-olumiant-pharmacoeconomic-review-report.pdf SR0597 Olumiant - CDEC Final Recommendation_for posting.pdf	Arthritis, Rheumatoid	Reimburse with clinical criteria and/or conditions	Complete	Dec 20, 2018	Aug 2, 2019	SR0597-000
Brigatinib (Alunbrig) for Non-...	Alunbrig	Brigatinib	pcodr_provfund-10167-BrigatinibAlunbrig_NSCLC.pdf 10167BrigatinibNSCLC_FnRec_approvedbyChair_NOREDACT_Post_01AUG2019_final.pdf 10167BrigatinibNSCLC_fnEGR_NOREDACT-ABBREV_01AUG2019_final.pdf 10167BrigatinibNSCLC_fnCGR_NOREDACT_POST01AUG2019_final.pdf 10167BrigatinibNSCLC_inRec_approvedbyChair_NOREDACT_Post_31May2019_final.pdf 10167BrigatinibNSCLC_PAGFeedbackSummary_FINAL_Post_01Aug2019_final.pdf 10167BrigatinibNSCLC_SubmitterFeedback_2019-06-14_Post_01Aug2019_final.pdf 10167BrigatinibNSCLC_PatientFeedback_LCC_2019-06-14_Post_01Aug2019_final.pdf 10167BrigatinibNSCLC_Combined_ClinicianFeedback_2019-06-14_Post_01Aug2019_final.pdf 10167BrigatinibNSCLC_Combined_PtGrp_COIs_Post_01Aug2019_final_Redacted.pdf 10167BrigatinibNSCLC_Combined_Clinician_COIs_01Aug2019_final_Redacted.pdf	NSCLC	Do not reimburse	Complete	Dec 5, 2018	Aug 1, 2019	PC0167-000
Keytruda for Melanoma Adjuvant...	Keytruda	Pembrolizumab	pcodr_provfund-10168-PembrolizumabKeytruda_MAT.pdf 10168PembrolizumabMAT_FnRec_31 July 2019__Post_01Aug2019_final.pdf 10168PembrolizumabMAT_fnEGR_NOREDACT-ABBREV_Post_01Aug2019_final.pdf 10168PembrolizumabMAT_fnCGR_REDACT_Post_01Aug2019_final.pdf 10168PembrolizumabMAT_inRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf 10168PembolizumabMAT_PAGFeedbackSummary_FINAL_Post_01Aug2019_final.pdf 10168PembrolizumabMAT_SubmitterFeedback_2019-06-12_Post_01Aug2019_final.pdf 10168PembrolizumabMAT_ClinicianFeedback_CCO_2019-06-14_Post_01Aug2019_final.pdf 10168PembrolizumabMAT_Combined_Patient_COIs_Post_01Aug2019_final_Redacted.pdf 10168PembrolizumabMAT_Combined_Clinician_COIs_Post_01Aug2019_final.pdf	Melanoma Adjuvant Treatment	Reimburse with clinical criteria and/or conditions	Complete	Dec 13, 2018	Aug 1, 2019	PC0168-000
Lutathera for Gastroenteropanc...	Lutathera	Lutetium Lu 177 dotatate	pcodr-provfund-10142-LutetiumLutathera_GEP_NETs.pdf 10142LutetiumLu177dotatateGEP-NET_fnRec_Post_01Aug2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_fnEGR_NOREDACT-ABBREV_Post_01Aug2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_fnCGR_NOREDACT_Post_01Aug2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_inRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_PAGFeedbackSummary_FINAL_Post_01Aug2019_draft.pdf 10142LutetiumLu177dotatateGEP-NET_SubmitterFeedback_2019-06-14_Post_01Aug2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_PatientFeedback_CNETS_2019-06-28_Post_01Aug2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_COI_Post_01Aug2019_final.pdf	Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)	Reimburse with clinical criteria and/or conditions	Complete	Jul 30, 2018	Aug 1, 2019	PC0142-000
patisiran	Onpattro	patisiran	SR0598_Onpattro-patient-input.pdf SR0598 Onpattro - CDEC Final Recommendation July 29, 2019 for posting.pdf sr0598-onpattro-clinical-review-report.pdf sr0598-onpattro-pharmacoeconomic-review-report.pdf	Polyneuropathy in hereditary transthyretin-mediated amyloidosis	Reimburse with clinical criteria and/or conditions	Complete	Jan 25, 2019	Jul 25, 2019	SR0598-000
Latanoprostene bunod	Vyzulta	latanoprostene bunod	sr0590-vyzulta-clinical-review-report.pdf sr0590-vyzulta-pharmacoeconomic-review-report.pdf sr0590-vyzulta-patient-input.pdf SR0590 Vyzulta - CDEC Final Recommendation July 26, 2019 _for posting.pdf	Open-angle glaucoma or ocular hypertension	Reimburse with clinical criteria and/or conditions	Complete	Nov 23, 2018	Jul 24, 2019	SR0590-000
Lenvima for Hepatocellular Car...	Lenvima	Lenvatinib	pcodr-profund-10175-LenvatinibLenvima_HCC.pdf 10175LenvatinibHCC_fnRec_2019-07-23_ApprovedByChair_Post_24Jul2019_final.pdf 10175LenvatinibHCC_inEGR_NOREDACT-ABBREV_EarlyCon_Post_24Jul2019_final.pdf 10175LenvatinibHCC_inCGR_NOREDACT_EarlyConv_Post_24Jul2019_final.pdf 10175LenvatinibHCC_inRec_ApprovedByChair_NOREDACT_Post_05Jul2019_final.pdf 10175LenvatinibHCC_PAGFeedbackSummary_FINAL_Post_24Jul2019_final.pdf 10175LenvatinibHCC_SubmitterFeedback_2019-07-19_Post_24Jul2019_final.pdf 10175LenvatinibHCC_Canadian Liver Foundation v2 2019-07-22_Post_24Jul2019_final.pdf 10175LenvatinibHCC_ClinicianFeedback_BCCancer_2019-07-18_Post_24Jul2019_final.pdf 10175LenvatinibHCC_CombinedPat_Post_24Jul2019_Redacted.pdf 10175LenvatinibHCC_Combined Clinician COIs_Post_24Jul2019_final.pdf	Hepatocellular Carcinoma (HCC)	Reimburse with clinical criteria and/or conditions	Complete	Feb 8, 2019	Jul 24, 2019	PC0175-000
ulipristal acetate	Fibristal	ulipristal acetate	SF0609 Fibristal - Group Patient Input June 28, 2019.pdf SF0609 Fibristal RfA - CDEC Final Recommendation July 30, 2019_for posting.pdf sf0609-fibristal-request-for-advice-clinical-review-report.pdf	Uterine fibroids (signs and symptoms)	Reimburse with clinical criteria and/or conditions	Complete	Mar 28, 2019	Jul 24, 2019	SF0609-000
Ninlaro for Multiple Myeloma (...	Ninlaro	Ixazomib	pcodr-provfund-10164-ixazomib-ninlaro_mm2nd-beyond.pdf 10164IxazomibMM_fnRec_2019-07-05_ChairApproved_Post_05Jul2019_final.pdf 10164IxazomibMM_fnEGR_NOREDACT-ABBREV_Post_05Jul2019_final.pdf 10164IxazomibMM_fnCGR_REDACT_Post_05Jul2019_final.pdf 10164IxazomibMM_inRec_2019-05-03_Approved_Post_03May2019_final.pdf 10164IxazomibMM_PAGFeedbackSummary_FINAL_Post_5Jul2019_final.pdf 10164IxazomibMM_SubmitterFeedback_2019-05-17_Post_05Jul2019_final.pdf 10164IxazomibMM_PatientFeedback_MC_2019-05-15_Post_05Jul2019_final.pdf 10164IxazomibMM_ClinicianFeedback_CCO_2019-05-16_Post_05Jul2019_final.pdf 10164IxazomibMM_Patient_COI_MC_2018-12-13_Post_05Jul2019_final_Redacted.pdf 10164IxazomibMM_Combined COIs_Post_05Jul2019_final Redacted.pdf	Multiple Myeloma (2nd-beyond)	Do not reimburse	Complete	Nov 30, 2018	Jul 5, 2019	PC0164-000
Abemaciclib for advanced or me...	Verzenio	Abemaciclib	pcodr-provfund-10161-AbemaciclibVerzenio_ABC.pdf 10161AbemaciclibMBC_fnRec_ApprovedbyChair_v01_2019-07-04_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_fnEGR_NOREDACT-ABBREV_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_fnCGR_NOREDACT_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_inRec_ApprovedbyChair_v01_Post_03May2019_final.pdf 10161AbemaciclibMBC_PAGFeedbackSummary_FINAL_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_SubmitterFeedback_2019-05-17_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_Combined PatientFeedback_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_ClinicianFeedback_CCO_2019-05-16_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_Combined Patient COIs_ Post_05Jul2019_final.pdf 10161AbemaciclibMBC_Combined COIs_Post_05Jul2019_final.pdf	Metastatic Breast Cancer	Reimburse with clinical criteria and/or conditions	Complete	Dec 3, 2018	Jul 5, 2019	PC0161-000
telotristat	Xermelo	telotristat	SR0580_telotristat_PI Submission.pdf SR0580 Xermelo - CDEC Final Recommendation July 3, 2019_For Posting.pdf sr0580-xermelo-clinical-review-report.pdf sr0580-xermelo-pharmacoeconomic-review-report.pdf	carcinoid syndrome	Do not reimburse	Complete	Sep 27, 2018	Jun 26, 2019	SR0580-000
Revlimid (in combo) bortezomib...	Revlimid	Lenalidomide	pcodr-provfund-10141-LenalidomideRevlimid_MM.pdf 10141LenalidomideBorDexMM_fnRec_2019-06-19_ApprovedbyChair_EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_fnEGR_NOREDACT-ABBREV_EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_fnCGR_REDACT_EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_inRec_approvedbyChair_NOREDACT_Post_31May2019_final.pdf 10141LenalidomideBorDexMM_PAGFeedbackSummary_FINAL__EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_SubmitterFeedback_2019-06-14_EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_ClinicianFeedback_CCO_2019-06-14__EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_PatientCOI_MC_2019-01-11_EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_Clinician_Combined_COIs_Post_19Jun2019_final_Redacted.pdf	Multiple Myeloma (+bortezomib+dex)	Reimburse with clinical criteria and/or conditions	Complete	Dec 21, 2018	Jun 19, 2019	PC0141-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 401 - 425 of 600

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Pharmacological Interventions for Vaping Cessation	Pharmacological Interventions for Vaping Cessation	Apr 13, 2021	Summary with Critical Appraisal	Completed	RC1357-000
Bupropion for Treatment Resistant Depression	RC1351 Bupropion for TRD Final.pdf	Apr 12, 2021	Summary with Critical Appraisal	Completed	RC1351-000
Models of Care for Chronic Pain: An Environmental Scan	Models of Care for Chronic Pain: An Environmental Scan Models of Care for Chronic Pain: Summarizing the Evidence	Apr 12, 2021	Environmental Scan	Completed	ES0350-000
Lenses and Spectacles to Prevent Myopia Worsening in Children	RC1349 Myopia children Final.pdf	Apr 9, 2021	Summary with Critical Appraisal		RC1349-000
Interferon Gamma Release Assay for the Identification of Latent Tuberculosis Infection in Rural and Remote Settings	RC1341 IGRA vs TST upgrade Final.pdf	Apr 9, 2021	Summary with Critical Appraisal	Completed	RC1341-000
Flash Glucose Monitoring Systems in Pediatric Populations with Diabetes	RC1354 FGM for Pediatrics Final.pdf	Apr 6, 2021	Summary with Critical Appraisal	Completed	RC1354-000
COVID-19 Impact on Intimate Partner Violence and Child Maltreatment	COVID-19 Impact on Intimate Partner Violence and Child Maltreatment	Mar 30, 2021			CI0145-000
Point-of-Care Testing of International Normalized Ratios for People on Oral Anticoagulants: A Rapid Qualitative Review	Point-of-Care Testing of International Normalized Ratios for People on Oral Ant…	Mar 30, 2021	Summary with Critical Appraisal	Completed	RC1334-000
Treatment Sequences of Androgen Receptor Targeted Agents for Patients with Prostate Cancer	Summary With Critical Appraisal - Rapid Response Report	Mar 17, 2021	Summary with Critical Appraisal	Completed	RC1347-000
Remote Monitoring Programs for Cardiac Conditions in Canada		Mar 12, 2021	Environmental Scan	Completed	ES0345-000
Interventions to influence the use of antibiotics for acute upper respiratory tract infections	Interventions to influence the use of antibiotics for acute upper respiratory t…	Mar 12, 2021	Summary with Critical Appraisal		RC1332-000
Onabotulinum Toxin A for Spasticity Associated with Multiple Sclerosis	Onabotulinum Toxin A for Spasticity Associated with Multiple Sclerosis	Mar 11, 2021	Summary with Critical Appraisal		RC1340-000
Remote Monitoring Programs for Cardiac Conditions in Canada		Mar 11, 2021	Environmental Scan		ES0345-000
Stellate Ganglion Block for the Treatment of Post-Traumatic Stress Disorder, Depression, and Anxiety	RC1339 SGB PTSD Final.pdf	Mar 3, 2021	Summary with Critical Appraisal	Completed	RC1339-000
Codeine for Pain Related to Caesarean Section: A Review of Clinical Effectiveness	RC1326 Codeine for C-section Pain Final.pdf	Mar 3, 2021	Summary with Critical Appraisal	Completed	RC1326-000
Codeine for Acute Dental Pain and Acute Pain Related to Dental Procedures	RC1325-Codeine-Dental-Pain Final.pdf	Mar 3, 2021	Summary with Critical Appraisal	Completed	RC1325-000
Yttrium 90 Microspheres for Advanced, Recurrent, or Inoperable Hepatocellular Carcinoma: A Review of Clinical and Cost Effectiveness	RD0059 Y90 Microspheres Final.pdf	Mar 1, 2021	Rapid Review with Expert Input	Completed	RD0059-000
Patient Navigation Programs for People With Dementia	Patient Navigation Programs for People With Dementia	Feb 24, 2021	Summary with Critical Appraisal	Completed	RC1333-000
Rapid Testing for the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance: A Review of Cost-Effectiveness	RC1328 GeneXpert Upgrade Econ Final.pdf	Feb 19, 2021	Summary with Critical Appraisal	Completed	RC1328-000
Incentives and Support Programs to Improve Adherence to Tuberculosis Treatment	RC1318 TB Treatment Adherence Final.pdf	Feb 18, 2021	Summary with Critical Appraisal	Completed	RC1318-000
Rituximab for the Treatment of Neuromyelitis Optica Spectrum Disorder	Rituximab for the Treatment of Neuromyelitis Optica Spectrum Disorder (Peer-re…	Feb 9, 2021	Peer-reviewed Summary with Critical Appraisal		RD0058-000
Gravity Drainage Versus Forced Suction Drainage for Patients With Excess Fluid in Pleural or Peritoneal Spaces	RC1327 Thoracentesis and Paracentesis Final.pdf	Feb 8, 2021	Summary with Critical Appraisal		RC1327-000
Workplace Electronic Health Promotion Campaigns for Tobacco Smoking Prevention or Cessation: A Review of Cost-Effectiveness	Workplace Electronic Health Promotion Campaigns for Tobacco Smoking Prevention …	Feb 2, 2021	Summary with Critical Appraisal	Completed	RC1335-000
Peripherally Inserted Central Catheters in Pediatric Patients Performed by Radiologists Using Fluoroscopy	RC1330 Pediatric PICC Insertions Final.pdf	Jan 22, 2021	Summary with Critical Appraisal		RC1330-000
The Canadian Medical Imaging Inventory 2019 - 2020		Jan 15, 2021	Optimal Use	Completed	OP0546-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 401 - 425 of 2132

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Newborn screening - Drugs for Rare Diseases Strategy			Jun 28, 2024	Health Technology Review	Technology Review	In Progress	HC0079-000
Methodology for Ethics Analysis in Pharmaceutical Reimbursement Reviews			Jun 28, 2024	Health Technology Review		In Progress	MG0027-000
Pharmaceutical Reviews Update — Issue 48			Jun 27, 2024	Reimbursement Review	Pharmaceutical Review Update
Endometrial Cancer		Final Report	Jun 27, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0045-000
NSCLC without actionable oncogenic alteration		Final Report	Jun 27, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0046-000
cannabidiol		Recommendation and Reasons Patient and Clinician Group Input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Jun 27, 2024	Reimbursement Review		Complete	SR0799-000
Choline Supplementation for Infants, Children, and Pregnant People		Choline Supplementation for Infants, Children, and Pregnant People	Jun 18, 2024	Health Technology Review	Rapid Review	Completed	RC1531-000
Interferons, Glatiramer Acetate, and Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome		Interferons, Glatiramer Acetate, and Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome	Jun 17, 2024	Health Technology Review	Rapid Review	Completed	RC1540-000
Nabilone for Chronic Non-Cancer Pain		Nabilone for Chronic Non-Cancer Pain	Jun 14, 2024	Health Technology Review	Rapid Review	Completed	RC1539-000
Infliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities		Infliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities	Jun 14, 2024	Health Technology Review	Rapid Review	Completed	RC1536-000
ravulizumab		Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Jun 14, 2024	Reimbursement Review		Complete	SR0785-000
Minimum Retesting Intervals for Lab Tests	Canada’s Drug Agency partnered with Choosing Wisely Canada to host a multidisciplinary panel of experts to provide guidance on the minimum retesting intervals of laboratory tests that are commonly repeated in hospitals, health authorities, and community laboratories across the country.	Final Guidance Report Technology Review - Minimum Retesting Intervals for Lab Tests Lipase Quick Guide Hemoglobin A1C Quick Guide Thyroid Stimulating Hormone Quick Guide Serum Protein Electrophoresis Quick Guide Antinuclear Antibody Quick Guide	Jun 11, 2024	Health Technology Review	Technology Review	Completed	HC0078-000
treosulfan		Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Jun 10, 2024	Reimbursement Review		Complete	PC0324-000
Anticytokine Therapy and Corticosteroids for Cytokine Release Syndrome and for Neurotoxicity Following T-Cell Engager or CAR T-Cell Therapy		Anticytokine Therapy and Corticosteroids for Cytokine Release Syndrome and for Neurotoxicity Following T-Cell Engager or CAR T-Cell Therapy	Jun 7, 2024	Health Technology Review	Rapid Review	Completed	RC1534-000
fidanacogene elaparvovec		Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Jun 5, 2024	Reimbursement Review		Complete	SG0802-000
Virtual Medicine Wards and Hospital-at-Home Programs	Virtual wards, also known as hospital-at-home programs, support the provision of inpatient-level acute medical care in a patient’s home. Our Horizon Scan presents existing evaluations of virtual ward and hospital-at-home programs for early supported discharge.	Virtual Medicine Wards and Hospital-at-Home Programs	Jun 4, 2024	Horizon Scan	Health Technology Update	Completed	EN0056-000
Cutaneous Melanoma		Final Report Proposed Project Scope	Jun 4, 2024	Reimbursement Review	Provisional Funding Algorithm	Active	PH0042-000
Point-of-Care Tests for COVID-19 and Influenza in Canada		Point-of-Care Tests for COVID-19 and Influenza in Canada	Jun 4, 2024	Horizon Scan	Health Technology Update	Completed	EN0055-000
Bayesian Hierarchical Models of Basket Trials in the Context of Economic Evaluation		Bayesian Hierarchical Models of Basket Trials in the Context of Economic Evalua…	May 31, 2024	Health Technology Review	Technology Review	Completed	MH0020-000
Alemtuzumab, Cladribine, Fingolimod, and Natalizumab as First-Line Treatments in Adult Patients With Highly Active Relapsing Multiple Sclerosis		Final Report Project Protocol	May 30, 2024	Health Technology Review	Health Technology Assessment	Completed	HT0038-000
Pharmaceutical Reviews Update — Issue 47			May 30, 2024	Reimbursement Review	Pharmaceutical Review Update
von Willebrand Factor [recombinant]		ST0639 Vonvendi - Final CPEC Recommendation March 22, 2021 for posting.pdf ST0639_Vonvendi_PI Submission.pdf Clinical Report Pharmacoeconomic Report	May 28, 2024	Reimbursement Review		Complete	ST0639-000
Drugs for Advanced Renal Cell Carcinoma: A Treatment Pattern Analysis			May 22, 2024	Health Technology Review	Technology Review	Active	HC0082-000
Newborn Screening for Congenital Cytomegalovirus in Canada	Congenital cytomegalovirus (cCMV) infection is a leading cause of childhood hearing loss. Our report provides a summary about newborn screening for cCMV in Canada, including whether screening is available in each province and territory, and if so, whether screening is universal or targeted.	Final Report	May 22, 2024	Health Technology Review	Policy Insight	Completed	CY0016-000
Colorectal cancer		Final Report	May 22, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0044-000